Hexarelin vs Ipamorelin: Potency, Selectivity, and Growth Hormone Release

Hexarelin and Ipamorelin are both growth hormone-releasing peptides (GHRPs) that act on the ghrelin/GHS-R1a receptor to stimulate pituitary GH release. They are often grouped together in literature reviews, but their pharmacology is meaningfully different. This guide breaks down potency, selectivity, downstream hormone effects, and what those differences mean for in-vitro research models.

At a glance

| Property | Hexarelin | Ipamorelin | |---|---|---| | Class | GHRP (6-mer) | GHRP (5-mer) | | GH release potency | Very high | Moderate–high | | Cortisol / prolactin release | Yes, dose-dependent | Minimal | | GHS-R1a selectivity | Lower | High | | Receptor desensitization | Faster | Slower | | Typical research half-life | ~55 min | ~120 min |

Mechanism

Both peptides bind the growth hormone secretagogue receptor (GHS-R1a) in the anterior pituitary and hypothalamus, mimicking endogenous ghrelin. Receptor activation triggers IP3/DAG signaling, intracellular calcium release, and pulsatile GH secretion independent of GHRH — though the two pathways are synergistic when stimulated together.

Where they diverge is off-target receptor activity. Hexarelin shows measurable affinity for CD36 and additional secondary binding sites, which is the likely mechanism behind its cortisol and prolactin elevation in animal models. Ipamorelin was specifically engineered to minimize that cross-reactivity.

Potency

Hexarelin is one of the most potent GHRPs ever characterized. In rat pituitary cell models it produces a higher peak GH response than GHRP-6, GHRP-2, or Ipamorelin at equimolar doses. Ipamorelin produces a cleaner but lower-amplitude release.

For comparative research, the practical implication is that Hexarelin generates a sharper, larger GH pulse but desensitizes the receptor faster — repeat administration in animal studies shows diminished response within 7–14 days. Ipamorelin's lower potency comes with more durable receptor responsiveness over chronic dosing windows.

Selectivity and side-effect profile

Ipamorelin is the most selective GHRP in the literature: studies in pigs and rats show GH release without significant cortisol, ACTH, or prolactin elevation. Hexarelin reliably elevates cortisol and prolactin in the same models — useful if a study is specifically examining HPA-axis crosstalk, but a confounder if the goal is isolated GH signaling.

Choosing between them in research

• Maximum GH pulse amplitude, short-term → Hexarelin
• Isolated GH signaling, chronic dosing → Ipamorelin
• HPA-axis or prolactin crosstalk studies → Hexarelin (the side-effect is the signal)
• Combined with a GHRH analog ([CJC-1295](/research/hubs/cjc-1295)) → Ipamorelin (cleaner additive effect, less desensitization)

Related research

• Ipamorelin product page
• CJC-1295 + Ipamorelin blend
• Growth hormone secretagogue research hub

Disclaimer

All content is for in-vitro research and educational use only. Not for human consumption. Always consult primary peer-reviewed literature and your institution's review board before designing a study.

Running the numbers for a protocol? Use the research calculators to convert mg, mL, and syringe units.